Zvonko Milicevic

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 8

Top Topics

Top Venues

Diabetes, obesity & metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Tim Heise, J Hans DeVries, Shweta Urva, Jing Li, Edward John Pratt, Melissa K Thomas, Kieren J Mather, Chrisanthi A Karanikas, Julia P Dunn, Axel Haupt, Zvonko Milicevic, Tamer Coskun
Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Diabetes care (2023)
Juan Pablo Frias, Enzo Bonora, Luis Nevarez Ruiz, Ying G Li, Zhuoxin Yu, Zvonko Milicevic, Raleigh Malik, M Angelyn Bethel, David A Cox
Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). Diabetes care 44 (3) (2021)
Juan Pablo Frias, Michael A Nauck, Joanna Van, Charles Benson, Ross Bray, Xuewei Cui, Zvonko Milicevic, Shweta Urva, Axel Haupt, Deborah A Robins
Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes, obesity & metabolism 22 (6) (2020)
Francesco Giorgino, Maria Yu, Axel Haupt, Zvonko Milicevic, Luis-Emilio Garcia-Perez
Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD-2 clinical trial. Diabetes, obesity & metabolism 21 (11) (2019)
Juan Pablo Frias, Alan G Wynne, Beata Matyjaszek-Matuszek, Dagmar Bartaskova, David A Cox, Brad Woodward, Ying G Li, Lai S Tham, Zvonko Milicevic
Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin. Diabetes, obesity & metabolism 21 (9) (2019)
Richard D Leslie, Paolo Pozzilli, Anne L Peters, Raffaella Buzzetti, Sudha S Shankar, Zvonko Milicevic, Imre Pavo, Jeremie Lebrec, Sherry Martin, Nanette C Schloot
Response to the comment on: "Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 trials". Diabetes, obesity & metabolism 20 (9) (2018)
Paolo Pozzilli, Paul Norwood, Esteban Jódar, Melanie Jane Davies, Tibor Ivanyi, Honghua Jiang, D Bradley Woodward, Zvonko Milicevic
Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9). Diabetes, obesity & metabolism 19 (7) (2017)
Michael A Nauck, Jean-Louis Frossard, Jamie S Barkin, Greg Anglin, Ingrid E Hensley, Kristine D Harper, Zvonko Milicevic
Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide. Diabetes care 40 (5) (2017)